Discover and read the best of Twitter Threads about #MPM
Most recents (6)
#OncoAlert Now online @Annals_Oncology is the phase III ETOP 9-15 trial (PROMISE-meso) of pembrolizumab vs chemotherapy for pretreated mesothelioma #MPM presented at #ESMO19 @myESMO @DrSanjayPopat @MdCurioni @GautschiOliver @NadalErnest @peters_solange
annalsofoncology.org/article/S0923-…
annalsofoncology.org/article/S0923-…
#OncoAlert Randomized 144 patients with relapsed #MPM to pembrolizumab vs chemo (gemcitabine or vinorelbine), no PDL1 selection. No difference in BICR PFS noted (HR 1.06) though RR favored pembro (22% vs 6%). 
#OncoAlert In this trial, 63% of patients receiving chemotherapy crossed over and with 17.5m median follow up, no difference in survival noted (OS HR 1.12). No impact of PDL1 expression on the bottom line. Somewhat disappointing but fortunate to have 1L data for IO in #MPM now.
#ESMO20 With some of the technical limitations, grateful for this discussion of the mesothelioma #MPM oral abstracts by @GautschiOliver @OncoAlert
#ESMO20 @GautschiOliver reviews the history of immunotherapy in #MPM, with early single arm trials showing efficacy but disappointing randomized trials of tremelimumab and of pembro vs chemo. Still, responses were seen, including his own patient with a 3y response. @OncoAlert
#ESMO20 That finally changed with #WCLC20 @IASLC with CheckMate 743 when first-line nivo/ipi improved OS compared to chemotherapy (OS HR 0.74), particularly in the non-epithelioid subtype (OS HR 0.46). @OncoAlert
#VPS20 Paul Baas presents the highly anticipated Checkmate-743 trial: a randomized phase III study of nivolumab + ipilimumab vs platinum + pemetrexed chemotherapy as 1L treatment in unresectable malignant pleural mesothelioma. Mature dataset. #MPM #LCSM #WCLC20 @IASLC
Phase III ADAURA study showed adjuvant osimertinib improves DFS (HR 0.17) in respected stage II-III NCSLC, no OS data yet
CTONG 1104 showed no OS benefit with 2 years adjuvant gefitinib vs chemo in node positive resected NSCLC
#ASCO20 Very promising results from PrECOG 0505 trial presented by @FordePatrick: Single arm phase II of durvalumab with cis/pem as 1L treatment for unresectable pleural mesothelioma (#MPM) #OncoAlert
#ASCO20 PrE0505 enrolled 55 patients (75% epithelioid) in 1y and treated with 6 cycles of standard cis/pem with durva 1120mg q3w followed by durva maintenance therapy (until PD). #OncoAlert
#ASCO20 Impressive OS numbers here with addition of durvalumab to cis/pem in #MPM with median of 20.4m and a 1y OS rate of 70.4%. Median PFS was 6.7m and RR was 56% (in the Australian DREAM trial RR was 48%). #OncoAlert
#ASCO20 The RAMES study was a phase II trial of 2nd line gemcitabine +/- ramucirumab for pleural mesothelioma (#MPM). VEGF is an enticing target. MAPS showed adding bev to cis/pem improved OS (not FDA approved) though LUME-meso (nintedanib + cis/pem) was negative. #OncoAlert
#ASCO20 RAMES was a 1:1 randomization of gem 1000mg/m2 d1/8 with or without ram 10mg/kg in 21d cycles. Primary endpoint was OS. Included MPM with PD after platinum/pemetrexed. Treated 161 patients, 85% epithelioid. #OncoAlert
#ASCO20 Addition of ramucirumab to 2nd line gemcitabine improved OS in #MPM. Median from 7.5m to 13.8m (HR 0.71). 1y OS rate 34% to 57%. PFS numerically better (3.3m to 6.2m, p=0.26). Note that RR not higher, mostly SD. The benefit is survival. #OncoAlert
